Study to Assess the Efficacy and Safety of Treatment With FOLFIRI-aflibercept Compared to Initial Treatment With FOLFIRI-aflibercept (for 6 Cycles) Followed by Maintenance With 5FU-aflibercept, in an Elderly Population With mCRC After Failure of an Oxaliplatin-based Regimen

Phase 2

Completed

• Conditions: Metastatic Colorectal Cancer
• Interventions: Drug: Aflibercept; Drug: Irinotecan; Drug: folinic acid (dl racemic); Drug: 5Fluorouracil; Drug: 5-FU

• Registration Number: NCT03279289
• Lead Sponsor: Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD)

Brief Summary

The purpose of this study is to assess the efficacy and safety of treatment with FOLFIRI-aflibercept compared to initial treatment with FOLFIRI-aflibercept (for 6 cycles) followed by maintenance with 5FU-aflibercept, in an elderly population with metastatic colorectal cancer (mCRC) after failure of an oxaliplatin-based regimen

Detailed Description

Not available

Study Timeline

• Study First Submitted: 2017-08-03
• Study First Submitted QC: 2017-09-08
• Study First Posted: 2017-09-12
• Study Start: 2017-10-25
• Primary Completion: 2023-02-09
• Study Completion: 2023-02-09
• Status Verified: 2023-04
• Last Update Submitted: 2023-04-12
• Last Update Posted: 2023-04-13

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 170

Inclusion Criteria

1. Signed and dated informed consent, and willing and able to comply with protocol requirements,
2. Histologically proven adenocarcinoma of the colon and/or rectum,
3. Existence of at least one measurable unidimensional lesion using CT or MRI based on the RECIST criteria, version 1.1
4. Patients with metastatic colorectal cancer (mCRC) that is resistant to or has progressed after a first line oxaliplatin-containing regimen for metastatic disease.
5. Age ≥70 years
6. World Health Organization (WHO) Performance status (PS) 0-2,
7. Hematological status: neutrophils (ANC) ≥1.5x109 /L; platelets ≥100x109 /L; haemoglobin ≥9 g/dL
8. Adequate renal function: Creatinine clearance ≥50 mL/min as calculated using the Cockcroft-Gault equation.
9. Adequate liver function: serum bilirubin ≤1.5 x upper normal limit (ULN), alkaline phosphatase (ALP) <5xULN
10. Proteinuria <2+ (dipstick urinalysis) or ≤1g/24hour.
11. Regular follow-up feasible.
12. Male patients with a partner of childbearing potential must agree to use contraception in addition to having their partner use another contraceptive method during the trial.

Exclusion Criteria

1. Uncontrolled hypercalcemia,

2. Pre-existing permanent neuropathy (NCI grade >2)

3. Uncontrolled hypertension (defined as systolic blood pressure >150 mmHg and/or diastolic blood pressure >100 mmHg), or history of hypertensive crisis, or hypertensive encephalopathy,

4. Concomitant protocol unplanned antitumor therapy (e.g. chemotherapy, molecular targeted therapy, immunotherapy),

5. Treatment with any other investigational medicinal product within 28 days prior to study entry.

6. Other serious and uncontrolled non-malignant disease,

7. History or evidence upon physical examination of CNS metastasis unless adequately treated (e.g. non irradiated CNS metastasis, seizure not controlled with standard medical therapy),

8. Patients classified as fragile or delicate according to the following criteria:

   1. Dependence in one or more activities of daily living according to the Katz Index of Independence in Activities of Daily Living (ADL) scale
   2. Three or more comorbidities when assessing the presence of the following processes: congestive heart failure; heart valve disease; coronary artery disease; chronic (obstructive or restrictive) pulmonary disease; cerebrovascular disease; peripheral neuropathy, chronic kidney failure; hypertension; diabetes; concomitant cancers; collagen vascular disease; chronic liver disease; and disabling arthritis
   3. Presence of geriatric syndromes: moderate-severe dementia; delirium in stressful situations (urinary or respiratory tract infection, angina or drugs); moderate-severe depression that interferes with the patient's usual activity; frequent falls (three or more per month); inattentiveness (who could help you in the event of an emergency?); urinary incontinence in the absence of stress, infection, diuretics or prostatic hyperplasia; faecal incontinence in the absence of diarrhoea or laxatives; osteoporotic fractures of large bones or vertebral compression fractures

9. Known Gilbert's syndrome

10. Intolerance to atropine sulfate or loperamide

11. Known dihydropyrimidine dehydrogenase deficiency

12. Treatment with CYP3A4 inducers unless discontinued > 7 days prior to inclusion

13. Any of the following in 3 months prior to inclusion: grade 3-4 gastrointestinal bleeding (unless due to resected tumor), treatment resistant peptic ulcer disease, erosive esophagitis or gastritis, infectious or inflammatory bowel disease, or diverticulitis.

14. Other concomitant or previous malignancy, except: i/ adequately treated insitu carcinoma of the uterine cervix, ii/ basal or squamous cell carcinoma of the skin, iii/ cancer in complete remission for >5 years,

15. Any other serious and uncontrolled non-malignant disease, major surgery or traumatic injury within the last 28 days

16. Patients with known allergy to any excipient to study drugs,

17. History of myocardial infarction and/or stroke within 6 months prior to inclusion, NYHA class III and IV congestive heart failure

18. Bowel obstruction.

19. Less than 28 days elapsed from prior radiotherapy

20. Patients with pernicious anemia or other megaloblastic anemias due to vitamin B12 deficiency

21. Patients with severe infections

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Group B	5Fluorouracil	FOLFIRI + aflibercept
Group A	folinic acid (dl racemic)	INDUCTION PHASE: 6 cycles of FOLFIRI + aflibercept MAINTENANCE PHASE: 5FU/LV + aflibercept
Group A	5Fluorouracil	INDUCTION PHASE: 6 cycles of FOLFIRI + aflibercept MAINTENANCE PHASE: 5FU/LV + aflibercept
Group B	folinic acid (dl racemic)	FOLFIRI + aflibercept
Group A	Aflibercept	INDUCTION PHASE: 6 cycles of FOLFIRI + aflibercept MAINTENANCE PHASE: 5FU/LV + aflibercept
Group A	Irinotecan	INDUCTION PHASE: 6 cycles of FOLFIRI + aflibercept MAINTENANCE PHASE: 5FU/LV + aflibercept
Group B	Irinotecan	FOLFIRI + aflibercept
Group A	5-FU	INDUCTION PHASE: 6 cycles of FOLFIRI + aflibercept MAINTENANCE PHASE: 5FU/LV + aflibercept
Group B	5-FU	FOLFIRI + aflibercept
Group B	Aflibercept	FOLFIRI + aflibercept

Primary Outcome Measures

Name	Time	Method
Progression-free survival	48 months

Secondary Outcome Measures

Name	Time	Method
Time to treatment failure	48 months
Time to progression	48 months
Overall survival	48 months
Objective response rate based on the RECIST criteria	48 months
Depth of response	48 months
Incidence and severity of AEs CTCAE v4.03 criteria	48 months
Incidence of dose adjustments and compliance	48 months
VES-13 score (Vulnerable Elders Survey) as the utility measure for health deterioration	48 months
Disease control rate	48 months

Trial Locations

Locations (1)

Spanish Cooperative Group for Digestive Tumour Therapy (TTD); 🇪🇸 Madrid, Spain